3 Top Ranked Healthcare ETFs in Focus - ETF News And Commentary
January 28 2014 - 2:04PM
Zacks
Healthcare has been one of the top performing sectors of 2013 and
this trend is likely to continue this year. This is largely thanks
to the robust performances by major drug companies in both the
pharma and biotech segments.
The space is clearly benefiting from the ongoing trends such as
increasing mergers and acquisition activities, promising new drugs,
growing demand in emerging markets, an aging population and
ever-increasing healthcare spending. In addition, the Affordable
Care Act (often known as Obamacare) – which looks to result in a
larger base of insured persons across the U.S. – is driving further
growth in the sector.
With expanded healthcare coverage, Obamacare will likely boost
revenues for many drug companies in the future, as a large number
of Americans would be able to afford medicines (read: Obamacare
Will Be Amazing for These Stocks and ETFs).
Further, the Zacks Industry Rank confirms the bullish trend for the
space, as healthcare actually has the best Rank for any industry at
the time of writing. About three-fifths of industries under
healthcare have Zacks Ranks in the top 42%, suggesting solid
trading in the coming months.
Given these positive trends, a good way to seek entry into the
broad healthcare world is by tilting toward companies in this
segment. While there are a number of ways to invest in this surging
corner of the market, a look at the top ranked ETFs could be a
lesser risky way to tap into the same broad trends (see: all the
Healthcare ETFs here).
Top Ranked Healthcare ETF in Focus
We have found a number of ETFs that have the top Zacks ETF Rank of
2 or ‘Buy’ rating in the broad healthcare space and are thus
expected to outperform in the months to come (read: all the Top
Ranked ETFs).
Among these top ranked ETFs, we pick the following three as good
choices to tap into the space. This trio has enjoyed strong
momentum in the year-to-date period, and has potentially superior
weighting methodologies which could allow these to continue leading
the healthcare space in the months ahead:
First Trust Health Care AlphaDEX Fund
(FXH)
This is one of the popular and liquid ETFs in the healthcare space
with AUM of around $1.6 billion and expense ratio of 0.70%. The
fund follows an AlphaDEX methodology and ranks stocks in the space
by various growth and value factors, eliminating the bottom ranked
25% of the stocks from inclusion in the benchmark (read: 4 Ways to
Play the Bullish Trend in Healthcare with ETFs).
This approach results in a basket of 75 stocks with a definite tilt
toward the large caps. Each security holds less than 2.7% of
assets, suggesting lower concentration risk of 7.18% (as per
XTF.com). Incyte (INCY), Jazz Pharma (JAZZ) and Illumina (ILMN) are
the top three elements in the basket.
Health care providers & services is the top sector with nearly
one-third allocation, followed by pharma (22.57%) and biotech
(19.01%). The ETF has added nearly 5.5% so far this year.
PowerShares Dynamic Healthcare Sector Portfolio
(PTH)
This fund follows the Dynamic Healthcare Sector Intellidex Index
and holds a basket of 60 U.S. companies. The product is relatively
unpopular with AUM of $94.5 million and charges 65 bps in fees and
expenses from investors. The ETF is moderately concentrated in its
top 10 holdings at nearly 26% with ILMN, Boston Scientific (BSX)
and Actavis (ACT) as the top three firms.
The product is well spread out across market cap levels with small
caps (41%), large caps (40%) and mid caps (19%). In terms of
industrial exposure, the fund is heavy on healthcare services that
make up for 47% share while medical equipment, biotech and pharma
round off to the next three spots. PTH returned over 5% in the
year-to-date time frame.
iShares U.S. Healthcare ETF
(IYH)
This fund provides exposure to 114 securities by tracking the Dow
Jones U.S. Health Care Index. This is a large cap centric fund with
Johnson & Johnson (JNJ) dominating the fund’s return at 11.34%
of total assets. Pharma takes the top spot from a sector look at
48%, closely followed by biotech (21%), medical equipment (17%) and
healthcare services (14%).
The product has amassed nearly $2 billion in its asset base and
charges 45 bps in annual fees. IYH is up 3.5% year-to-date (read: 3
Pharma ETFs Leading the Healthcare Sector).
Bottom Line
The trio has clearly outpaced the broad market fund (SPY) and the
broad sector fund (XLV) by wide margins. This outperformance and a
promising trend going forward are expected to continue given the
demographic shift in the U.S. as well as the insatiable demand for
new treatments and drugs for myriad illnesses. Given this,
investors should definitely consider these top ranked ETFs to ride
the surging healthcare space.
Want the latest recommendations from Zacks Investment Research?
Today, you can download
7 Best Stocks for the Next 30
Days. Click to get this free report >>
FT-HEALTH CARE (FXH): ETF Research Reports
ISHARS-US HLTHC (IYH): ETF Research Reports
PWRSH-DYN HLTHC (PTH): ETF Research Reports
SPDR-HLTH CR (XLV): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment Research
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days. Click
to get this free report
Health Care Select Sector (AMEX:XLV)
Historical Stock Chart
From Nov 2024 to Dec 2024
Health Care Select Sector (AMEX:XLV)
Historical Stock Chart
From Dec 2023 to Dec 2024